Hilmi ATASEVEN, İihami YÜKSEL, Mehmet İBİŞ, Ömer BAŞAR, H. Mehmet TÜRK

The Association of Autoimmune Hepatitis and Thyroid Cancer: Case Report

Otoimmün hepatit kronik, progresif bir karaciğer hastalığıdır. Bu hastalar genellikle immünsüpresif tedaviye yanıt verirler. Kortikosteroid ve azatioprin ile tedavi, remisyonu sağlamada köşe taşıdır. Gerekirse diğer immünsüpresif ilaçlar da tedavide kullanılmaktadır. İmmünsüpresif tedavi sonrası malignite gelişimi bilinmektedir. Ayrıca otoimmün hastalıklarla ilişkili lenfoproliferatif hastalıklar da önceden bildirilmiştir. Ancak otoimmün hepatitle birlikte diğer doku malignitelerinde birliktelik daha önce sunulma-mıştır. Biz bu yazıda otoimmün hepatitli bir hastada tedaviye başladıktan 17 ay sonra tiroid papiller karsinoma gelişimini sunduk.

Anahtar Kelimeler:

Otoimmün hepatit, tiroid kanseri, immünsüpresif tedavi, çocukluk çağı.

Otoimmün Hepatit ve Tiroid Kanseri Birlikteliği: Olgu Sunumu

Autoimmune hepatitis is a chronic Progressive liver disease. Patients vvith autoimmune hepatitis usually respond to immu-nosuppressive treatment. Treatment vvith corticosteroids and azathioprine is a milestone in achieving remission but other immu-nosuppressive drugs are also used when necessary. Development of malignancies follovving immunosuppressive treatment is well-known. İn addition, lymphoproliferative disorders associated vvith autoimmune diseases has been reported previously. Co-existence of autoimmune hepatitis and malignancies in other tissues, hovvever, has not been presented before. İn this report, we presented a case vvith autoimmune hepatitis developing thyroid papillary carcinoma 17 months after the initiation of therapy.

Keywords:

Autoimmune hepatitis, thyroid cancer, immunosuppressive treatment, childhood.,

PDF

___

Medina J, Garcia-Buey L, Moreno-Otero R. Review article: Immunopathogenetic and therapeutic aspects of autoimmu- ne hepatitis. Aliment Pharmacol Ther 2003;17:1-16.
Montella M, Pezzullo L, Crispo A, et al. Risk of thyroid can- cer and high prevalence of hepatitis C virüs. Oncol Rep 2003;10:133-6.
Behrand M, von VVasielevvski R, Brabant G. Simultaneous medullary and papillary microcarcinoma of thyroid in a pati- ent with secondary hyperparathyroidism. Endocr Pathol 2002;13:65-73.
Ondrus D, Pribyiincova V, Breza J, et al. The incidence of tumoers in renal transplant recipients with iong-term immu- nosuppressive therapy. Int Urol Nephrol 1999;31:417-22.
McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: Post-graft neoplasia 1968-1999, comparing azathioprine only with cyciosporin- based regimes in a singie centre. d in Transpl 2000;193-202.
Deeg HJ, Socie G, Schoch G, et al. Malignancies after mar- row transplantation for aplastic anemia and fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386-92.
Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-meianoma skin cancers and glucocorticoid therapy. Br J Cancer 2001;85:683-6.
Saeian K, Franco J, Komorowski RA, Adams MB. Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: A case series. Liver Transpl Surg 1999;5:46-9.
Wang KK, Czaja Ad. Hepatocellular carcinoma in corticos- teroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988;8:1679-83.
ViteriA, VernaceSJ, SchaffnerF. Extrahepatic maiignancy in chronic liver disease: Report of six cases. Gastroenteroiogy 1976;71:1075-8.
Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic iymphocytic thyroiditis and thyroid papil lary carcinoma: A study of surgical cases among Japanese, and white and African Americans. Cancer 1995; 76:2313-8.
Balkvvill F, Mantovani A. Inflammation and cancer: Back to Virchovv? Lancet 2001;357:539-45.
Imai H, Nakano Y, Kiyosavva K, Tan EM. Increasing titers and changing specificities of antinuciear antibodies in pati ents with chronic liver disease who deveiop hepatocellular carcinoma. Cancer 1993;71:26-35.